NASDAQ Firm's Patents Could Have Huge Implications on $13B Market

Alzheimer's disease has always been a tough challenge. In fact, just a few years ago Big Pharma all but abandoned their hopes on treating it.

But 2024 is changing that.

Over 134 drugs are now in development. Making a small firm with a critical patent... look like a prime buyout target.

This tiny NASDAQ has developed a unique treatment. Unlike anything on the market - not a drug, but a patented molecule. One that's having remarkable results.

Big Pharma is already paying close attention to potential future acquisitions. And with the Alzheimer's drug market set to hit $13 billion, the potential is enormous.

Don't miss out on what could be a pivotal moment in medical history.

And what has potential to be the single most pivotal opportunity in the market today.

This message is a paid advertisement for InMed Pharmaceuticals Inc., (NASDAQ: INM) from i2i Marketing Group, LLC. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,500.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with i2i Marketing Group, LLC. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals Inc., (NASDAQ: INM) on i2iMarketing Group's website for additional information about the relationship between i2i Marketing Group and InMed Pharmaceuticals Inc., (NASDAQ: INM).